Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Non-Current Assets came in at $31.3 million in Q2 2026, up 12.25% YoY from $27.9 million in Q2 2025, and down 5.77% on a QoQ basis from $33.3 million in Q1 2026.
Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Non-Current Assets data on file, last reported at $31.3 million in Q2 2026.
- Quarterly Non-Current Assets rose 12.25% year-over-year to $31.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $124.4 million (up 8.65% YoY) and the FY2025 annual result came in at $34.7 million, up 22.82% from the prior year.
- Non-Current Assets slipped to $31.3 million in Q2 2026, from $33.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $47.5 million in Q1 2023 to a low of $25.1 million in Q3 2025.
- A 5-year average of $33.6 million and a median of $32.3 million in 2026 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 347.81% — and 2024, when it tumbled 36.38%.
- Tracing BCYC's Non-Current Assets over 5 years: stood at $41.2 million in 2022, then dropped by 18.8% to $33.5 million in 2023, then dropped by 15.57% to $28.3 million in 2024, then increased by 22.82% to $34.7 million in 2025, then declined by 9.71% to $31.3 million in 2026.
- The last three Non-Current Assets figures came in at $31.3 million (Q2 2026), $33.3 million (Q1 2026), and $34.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 31.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.34 Mn |
| Mar 31, 2026 | 33.26 Mn |
| Dec 31, 2025 | 34.71 Mn |
| Sep 30, 2025 | 25.14 Mn |
| Jun 30, 2025 | 27.92 Mn |
| Mar 31, 2025 | 27.81 Mn |
| Dec 31, 2024 | 28.26 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 29.10 Mn |
| Mar 31, 2024 | 31.18 Mn |
| Dec 31, 2023 | 33.48 Mn |
| Sep 30, 2023 | 35.65 Mn |
| Jun 30, 2023 | 45.74 Mn |
| Mar 31, 2023 | 47.55 Mn |
| Dec 31, 2022 | 41.23 Mn |
| Sep 30, 2022 | 35.86 Mn |
| Jun 30, 2022 | 36.99 Mn |
| Mar 31, 2022 | 29.80 Mn |
| Dec 31, 2021 | 21.24 Mn |
| Sep 30, 2021 | 8.46 Mn |